Avalanche Biotechnologies, Inc.

Q: Sep 30 2025

Q: Jun 30 2025

Q: Mar 31 2025

FY: Dec 31 2024

FY: Dec 31 2024

Q: Sep 30 2024

Q: Jun 30 2024

Q: Mar 31 2024

FY: Dec 31 2023

Q: Sep 30 2023

Q: Jun 30 2023

Q: Mar 31 2023

FY: Dec 31 2022

Q: Sep 30 2022

Q: Jun 30 2022

Q: Mar 31 2022

FY: Dec 31 2021

Q: Sep 30 2021

Q: Jun 30 2021

Q: Mar 31 2021

Completion of Acquisition or Disposition of Assets

Regulation FD Disclosure

Termination of a Material Definitive Agreement

Entry into a Material Definitive Agreement

Regulation FD Disclosure

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

Regulation FD Disclosure

Results of Operations and Financial Condition

2.02,9.01

7.01,8.01,9.01

5.07

5.02

2.02,9.01

3.03,5.03,9.01

2.02,9.01

7.01,8.01,9.01

Certification of termination of registration of a class of securities (Section 12(g))

Notice of Effectiveness

Notice of Effectiveness

Notice of Effectiveness

Post Effective Amendment to S-8

Post-effective amendment to a registration statement

Post Effective Amendment to S-8

Post Effective Amendment to S-8

Post Effective Amendment to S-8

Post Effective Amendment to S-8

Post Effective Amendment to S-8

Post Effective Amendment to S-8

Post Effective Amendment to S-8

Post Effective Amendment to S-8

Post Effective Amendment to S-8

Post Effective Amendment to S-8

Post Effective Amendment to S-8

Post Effective Amendment to S-8

Post Effective Amendment to S-8

Notification of removal from listing and/or registration on a national securities exchange

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Preliminary Proxy Statement

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Preliminary Proxy Statement

Additional Information for Proxy Statement/ Votes

Definitive Proxy Statement

Additional proxy soliciting materials filed by a non-management party

Additional proxy soliciting materials filed by a non-management party

Additional proxy soliciting materials filed by a non-management party

Additional Information for Proxy Statement/ Votes

Additional proxy soliciting materials filed by a non-management party

Additional proxy soliciting materials filed by a non-management party

Additional proxy soliciting materials filed by a non-management party

Hong Soo

Seyedkazemi Setareh

Ozden Rabia Gurses

Lupher, Jr. Mark L.

Soparkar Peter

Nicholson, C. David

Fischer Laurent

Svoronos Dawn

Machado Patrick

Whitcup Scott M

Rubinstein Linda M

Tuckson Reed Vaughn

Scopa James Paul

Kiss Szilard

ELI LILLY & Co

Adverum Biotechnologies, Inc.

Frazier Life Sciences Public Fund, L.P.; FHMLSP, L.P.; FHMLSP, L.L.C.

Frazier Life Sciences Public Fund, L.P.

BML Investment Partners, L.P.

Fischer Laurent

No description available

Annual Report Scanned (Paper)

Annual Report Scanned (Paper)

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC

Letter from the SEC

Correspondence with the SEC

Annual Report Scanned (Paper)

Letter from the SEC

Letter from the SEC

Correspondence with the SEC

No description available

No description available

No description available

Correspondence with the SEC